title: Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.
abstract: To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4(+) and CD8(+) T cells in 324 subjects. Regression models--adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study--revealed that high pretreatment CD8(+) T cell activation predicted virologic failure (P=.046). Additional models showed the greatest increase in CD4(+) T cell counts in subjects with highest pretreatment naive CD4(+) T cell counts (P<.0001), which was enhanced by high CD4(+) and low CD8(+) T cell activation. Total lymphocyte count also predicted a subsequent CD4(+) T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection.
authors.affiliation: Beth Israel Medical Center, New York, New York, USA. mildvan@ix.netcom.com
authors.forename: Donna
authors.initials: D
authors.lastname: Mildvan
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Bosch
authors.forename: Ryung S
authors.initials: RS
authors.lastname: Kim
authors.forename: John
authors.initials: J
authors.lastname: Spritzler
authors.forename: David W
authors.initials: DW
authors.lastname: Haas
authors.forename: Daniel
authors.initials: D
authors.lastname: Kuritzkes
authors.forename: Jonathan
authors.initials: J
authors.lastname: Kagan
authors.forename: Mostafa
authors.initials: M
authors.lastname: Nokta
authors.forename: Victor
authors.initials: V
authors.lastname: DeGruttola
authors.forename: Melanie
authors.initials: M
authors.lastname: Moreno
authors.forename: Alan
authors.initials: A
authors.lastname: Landay
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006454:Hemoglobins / Q000276:immunology / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000737:chemistry / Q000235:genetics; D012044:Regression Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D044966:Anti-Retroviral Agents; D006454:Hemoglobins; D012367:RNA, Viral